Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA MRD Monitoring in Resected Pancreatic Cancer
NCT05802407Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Randomised, open-label trial in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Disease-free survival at 36 months. Started Feb 2023; status: recruiting.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05802407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802407.